Program
ETBX-071
Also written as “ETBX-071 (PSA-based Oncolytic Virus)”.
Its studies are mostly in Prostatic Neoplasms, led by ImmunityBio.
Furthest: phase 2, since Dec 20, 20242 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| ImmunityBio | 20 open or running | phase 2since Dec 20, 2024 | Dec 20, 2024 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 20, 2024First studies: 2 phase 2 studies in Prostatic NeoplasmsFirst studyNCT06765954, NCT06765902
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06765902Prostatic Neoplasms | 2 | Withdrawn | Jan 31, 2031 | 0 |
| NCT06765954Prostatic Neoplasms | 2 | Withdrawn | Jan 31, 2031 | 0 |
How it is read
Names in the registry
- “ETBX-071”, 1 entry
- “ETBX-071 (PSA-based Oncolytic Virus)”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.